| CPC C07D 519/00 (2013.01) [A61K 31/519 (2013.01); A61P 35/00 (2018.01); A61P 43/00 (2018.01); C07D 487/04 (2013.01)] | 19 Claims |
|
1. A compound of formula (I):
 or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein:
X is CH or N;
R1 is —CH3;
R2 and R3 are independently selected from hydrogen and C1-4alkyl;
Q is C or N;
wherein when Q is C then either:
(i) R4 is amino, aminoC1-4alkyl or monoC1-4alkylamino;
R5 is hydrogen, C1-4alkyl, halogen, hydroxyC1-4alkyl, C1-4alkoxy, haloC1-4alkyl or C1-4alkoxyC1-4alkyl;
or
(ii) R4 and R5 together with Q form a four- to six-membered ring that can optionally contain 1 to 3 heteroatoms or groups independently selected from N, O, S, NH, C(O) and S(O)m, and said ring formed by R4 and R5 can be unsubstituted or substituted with 1 to 4 groups independently selected from amino, halogen, haloC1-4alkyl, hydroxyl, methoxy, methylamino, and C1-4alkyl, and m is selected from 1 and 2; and
wherein when Q is N then:
R4 is absent; and
R5 is hydrogen;
R6 and R7 are independently selected from halogen, C1-4alkyl, hydroxyC1-4alkyl and hydroxyl provided that when Q is N then R6 or R7 are not halogen or hydroxyl;
Or, any two groups selected from R2, R3, R6 and R7 together form a one- to three-membered bridge group selected from C1-3alkylene, C2-3alkenylene, methylene-NRq-methylene and methylene-O-methylene, wherein the bridge group is optionally substituted by a group selected from C1-4alkyl, hydroxyl and halogen and Rq is selected from hydrogen and C1-4alkyl;
Or, R4 and R7 form a four- to six-membered ring containing a N atom;
Or, R5 and R7 form a three- to six-membered ring;
Or, R6 and R7 form a direct bond;
a is selected from 0, 1 and 2;
b is selected from 0, 1 and 2;
c is selected from 0, 1 and 2;
Or, Q is C, c is 2, R4 is hydrogen and the two R7 join to form a 4 to 6 membered nitrogen containing ring;
Ring A is either:
(i) a five-membered nitrogen-containing heterocyclic ring wherein the heterocyclic ring optionally contains one or two additional heteroatoms selected from N, O and S, or
(ii) a six-membered aromatic nitrogen-containing heterocyclic ring, wherein the heterocyclic ring optionally contains one or two additional heteroatoms selected from N, O and S; or
(iii) a six-membered non-aromatic nitrogen-containing heterocyclic ring, wherein the heterocyclic ring optionally contains one or two additional heteroatoms selected from N and S;
R8 is selected from hydrogen, C1-4alkyl, haloC1-4alkyl and halogen;
R9 is selected from hydrogen and halogen;
R10 is selected from haloC1-4alkyl, C1-4alkyl, halogen, hydrogen and C1-4alkoxy;
R11 are independently selected from halogen, cyano, cyanoC1-4alkyl, hydroxyl, oxo (═O), C1-4alkyl optionally substituted with five- or six-membered heterocyclic group containing 1 or 2 heteroatoms selected from O, N, and S, haloC1-4alkyl, C1-4alkoxy, hydroxylC1-4alkyl, C1-4alkoxyC1-4alkyl, C1-4alkylsulfone, amino, monoC1-4alkylamino, diC1-4alkylamino, aminoC1-4alkyl, —C1-4alkylene-C(═O)NH(2-q)(C1-6alkyl)q), —C1-4alkylene-NHC(═O)C1-6alkyl, sulfonamide, sulfonamideC1-4alkyl, 3 to 6 membered cycloalkyl, C1-4alkyl substituted with 3 to 6 membered cycloalkyl, five- or six-membered unsaturated heterocyclic group containing 1, 2, 3 or 4 heteroatoms selected from O, N, and S, and optionally substituted four- to six-membered saturated heterocyclic group containing 1 or 2 heteroatoms selected from O, N, and S where the optional substituent is selected from C1-4alkyl;
q is selected from 0, 1 and 2; and
d is selected from 0, 1 and 2.
|